Y-mAbs gets NCCN recommendation for neuroblastoma treatment

Stock Information for Y-mAbs Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Y-mAbs Therapeutics Inc.

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.